Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Syndax Pharmaceuticals showed better-than-expected financials, yet major investors sold off shares.
Syndax Pharmaceuticals reported a smaller-than-expected loss and higher revenue in the fourth quarter.
Despite this, several major investors, including Brevan Howard Capital Management and Schonfeld Strategic Advisors, reduced their stock holdings in the company.
Stifel Financial Corp increased its holdings.
The company focuses on developing cancer therapies.
3 Articles
Syndax Pharmaceuticals mostró mejores resultados financieros de lo esperado, sin embargo, los principales inversionistas vendieron sus acciones.